Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
Commercial production is expected to begin soon
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
Subscribe To Our Newsletter & Stay Updated
